• Talabostat mesylate: Cancer Assay Workflows

  2026-08-27

  Talabostat mesylate, also known as PT-100, supports parallel investigation of DPP4/FAP biology, tumor–stroma signaling, and immune readouts. This practical guide separates validated product applications from exploratory NLRP1 experiments inspired by recent inflammasome research.

• EZ Cap™ Mouse IL-12 mRNA (m1Ψ) in Extrahepatic Studies

  2026-08-26

  Explore how EZ Cap™ Mouse IL-12 mRNA (m1Ψ) links transcript chemistry, cytokine biology, and extrahepatic delivery design. This evidence-based guide translates virus-mimicking particle research into practical decisions for immunotherapy research mRNA workflows.

• Porcupine Inhibition for Sclerosteosis: Study Insights

  2026-08-26

  The 2025 Bone Research study identifies porcupine inhibition with LGK974 as a potential pharmacological strategy for reducing excessive Wnt-driven bone formation in sclerosteosis. In osteoblast cultures and Sost-deficient mice, LGK974 suppressed osteogenic activity and reduced selected trabecular and cortical bone measures, while also revealing possible sex-dependent differences in pathway response.

• Morin: Podocyte Energy Assay Workflow

  2026-08-25

  Morin combines pathway-focused mitochondrial research with fluorescent metal-ion sensing, creating a versatile workflow for diabetic kidney injury and biochemical assays. This guide translates recent podocyte findings into practical preparation, dosing, readout, and troubleshooting strategies.

• Trelagliptin, RUNX2, and Osteoblast Differentiation

  2026-08-25

  The 2021 reference study shows that trelagliptin promotes osteoblastic differentiation and mineralization in MC3T3-E1 cells, with increased RUNX2 and AMPK activation. Its findings suggest a possible bone-forming application for a long-acting DPP-4 inhibitor, while remaining limited to an in vitro preclinical model.

• Patient-Derived Gastric Cancer Assembloids

  2026-08-24

  Shapira-Netanelov and colleagues developed patient-derived gastric cancer assembloids by combining tumor organoids with matched stromal cell subpopulations from the same tumor tissue. The model captured tumor–stroma effects on gene expression and drug response, providing a more physiologically relevant platform for biomarker analysis, resistance studies, and personalized treatment testing.

• Anagliptin (SK-0403) in Vascular Research

  2026-08-23

  Use Anagliptin (SK-0403) to connect DPP-4 inhibition studies with functional vascular assays, rather than treating glycemic activity and vascular biology as separate questions. This guide translates rabbit-aorta findings into practical organ-bath workflows, mechanism controls, and troubleshooting decisions focused on Kv channels and SERCA pump regulation.

• HRP Goat Anti-Mouse IgG in Gout Research

  2026-08-22

  Explore how Affinity-Purified Goat Anti-Mouse IgG (H+L), HRP Conjugated supports rigorous protein detection in gout-like inflammation studies. This guide connects NLRP3 biology with assay design, controls, normalization, and practical secondary-antibody selection.

• Neuromedin S (rat): GPCR Workflow Guide

  2026-08-21

  Neuromedin S (rat) provides a rat peptide agonist for controlled studies of neuromedin U receptor signaling and related GPCR/G protein signaling workflows. This guide covers preparation, handling, assay controls, and interpretation boundaries; the reagent is for scientific research only and not for diagnostic, therapeutic, or medical use.

• NU7441: Designing Rigorous DNA-PK Assays

  2026-08-21

  NU7441 and KU-57788 enable selective interrogation of DNA-PK-dependent repair, but their greatest value emerges when biochemical, cellular, and genetic readouts are integrated. This guide translates modern kinase-pharmacology principles into more rigorous DNA repair research, oncology research, and cell cycle assay design.

• Gramine Drives Ferroptosis in TNBC via CUL3–MTDH

  2026-08-20

  This study identifies gramine as a candidate inhibitor of triple-negative breast cancer and links its activity to a previously underexplored CUL3–MTDH regulatory axis. By combining target-engagement assays, ferroptosis rescue experiments, genetic perturbation, and xenograft models, the authors show how CUL3 modulation can promote oxidative, iron-dependent cancer-cell death.

• Metal-Free Carbon Nanozymes for Sensitive ALP Detection

  2026-08-20

  The reference study develops a metal-free carbon-dot nanozyme assay in which alkaline phosphatase hydrolysis of pyrophosphate converts an inhibited catalytic system into a colorimetric turn-on signal. Kinetic analysis identifies pyrophosphate as a noncompetitive inhibitor at a site distinct from the principal nanozyme catalytic site, enabling ALP activity measurement across 0.010–0.200 U/L with a 0.009 U/L detection limit.

• Transcranial K+ Channelrhodopsin Suppresses Seizures

  2026-08-19

  The reference study engineered HcKCR1-hs, a highly light-sensitive, moderately K+-selective channelrhodopsin, to inhibit neuronal hyperactivity through the intact skull. In multiple mouse status epilepticus models, transcranial activation delayed seizures, reduced seizure burden, and improved survival, while also highlighting important translational limitations.

• Trelagliptin Succinate: Mechanism and Research Use

  2026-08-19

  Trelagliptin succinate, also called SYR-472 succinate, is a long-acting selective DPP-4 inhibitor for diabetes mellitus research. Evidence in differentiated adipocytes links DPP-4 enzyme inhibition with PI3K/AKT signaling, GLUT4 translocation, glucose uptake, and reduced adipokine-associated insulin resistance.

• BGJ398 for FGFR Signaling and Cancer Research

  2026-08-18

  BGJ398 (NVP-BGJ398) enables selective interrogation of FGFR1, FGFR2, and FGFR3 in cancer-cell, signaling, apoptosis, and developmental-tissue workflows. This guide connects practical assay design with a recent study showing how differential Fgf10/Fgfr2 activity shapes genital development.

457 records 7/31 page Previous Next First page 上5页 678910 下5页 Last page